Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have been given a consensus rating of “Moderate Buy” by the nine research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $66.13.

JANX has been the subject of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $100.00 price target on shares of Janux Therapeutics in a research note on Monday. HC Wainwright reaffirmed a “buy” rating and set a $63.00 price target on shares of Janux Therapeutics in a research note on Monday, August 19th. Wedbush reaffirmed an “outperform” rating and set a $74.00 price target on shares of Janux Therapeutics in a research note on Thursday, August 8th. Scotiabank decreased their price target on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a research note on Friday, August 9th. Finally, Stifel Nicolaus initiated coverage on shares of Janux Therapeutics in a research note on Friday, September 6th. They set a “buy” rating and a $70.00 price target for the company.

Janux Therapeutics Stock Performance

NASDAQ JANX opened at $48.32 on Thursday. The business has a 50 day simple moving average of $43.28 and a 200 day simple moving average of $44.19. Janux Therapeutics has a 52-week low of $5.65 and a 52-week high of $65.60. The stock has a market cap of $2.51 billion, a price-to-earnings ratio of -39.61 and a beta of 3.57.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Wednesday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.20. Janux Therapeutics had a negative return on equity of 8.78% and a negative net margin of 291.17%. The business had revenue of $8.90 million during the quarter, compared to analysts’ expectations of $0.77 million. Janux Therapeutics’s revenue was up 709.1% on a year-over-year basis. On average, analysts predict that Janux Therapeutics will post -1.18 EPS for the current year.

Insider Activity

In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 158,031 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $47.00, for a total transaction of $7,427,457.00. Following the completion of the sale, the insider now owns 2,959,175 shares of the company’s stock, valued at approximately $139,081,225. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders sold 268,578 shares of company stock valued at $12,071,151. 35.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Janux Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Capstone Investment Advisors LLC acquired a new stake in Janux Therapeutics during the 1st quarter valued at $1,969,000. Janus Henderson Group PLC lifted its holdings in Janux Therapeutics by 1.8% during the 1st quarter. Janus Henderson Group PLC now owns 1,965,546 shares of the company’s stock valued at $73,961,000 after purchasing an additional 34,069 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new position in Janux Therapeutics during the 1st quarter worth $739,000. Virtu Financial LLC bought a new position in Janux Therapeutics during the 1st quarter worth $609,000. Finally, Vanguard Group Inc. increased its position in Janux Therapeutics by 38.6% during the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock worth $51,127,000 after buying an additional 378,477 shares during the period. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.